Biosimilar Antibodies

Emerfetamab Biosimilar – Anti-CD33;CD3E mAb – Research Grade, ProteoGenix, PX-TA1663

Description of Emerfetamab Biosimilar - Anti-CD33;CD3E mAb - Research Grade Introduction Emerfetamab Biosimilar, also known as Anti-CD33,CD3E mAb – Research Grade, is a monoclonal antibody that has shown promising results in the treatment of various cancers. This biosimilar is designed to target the CD33 and CD3E proteins, which are known to play a crucial role in the development and progression of cancer. Structure of Emerfetamab Biosimilar Emerfetamab Biosimilar is a recombinant humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains are made up of 448 amino acids, while the light chains consist of 214 amino acids. The antibody has a molecular weight of approximately 150 kDa. Mechanism of Action The primary target of Emerfetamab Biosimilar is the CD33 protein, which is expressed on the surface of cancer cells. This protein is involved in the survival and growth of cancer cells. The antibody binds to CD33 and triggers a series of events that lead to the destruction of cancer cells. Additionally, Emerfetamab Biosimilar also targets the CD3E protein, which is found on the surface of T-cells. This binding activates the T-cells and enhances their ability to attack and kill cancer cells. Applications of Emerfetamab Biosimilar Emerfetamab Biosimilar has shown promising results in the treatment of various types of cancer, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL). It has also been studied in clinical trials for the treatment of solid tumors such as breast cancer and lung cancer. Acute Myeloid Leukemia (AML) AML is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal white blood cells. Emerfetamab Biosimilar has shown significant efficacy in treating AML, particularly in patients who have relapsed or are refractory to other treatments. Myelodysplastic Syndrome (MDS) MDS is a group of disorders in which the bone marrow does not produce enough healthy blood cells. Emerfetamab Biosimilar has shown promising results in treating MDS by targeting the abnormal cells and promoting their destruction. Acute Lymphoblastic Leukemia (ALL) ALL is a type of cancer that affects the white blood cells, particularly the lymphocytes. Emerfetamab Biosimilar has shown potential in treating ALL by targeting the CD33 protein, which is highly expressed in these cancer cells. Solid Tumors Emerfetamab Biosimilar has also been studied in clinical trials for the treatment of solid tumors such as breast cancer and lung cancer. The antibody’s ability to target both CD33 and CD3E proteins makes it a promising treatment option for these types of cancers. Research Grade Emerfetamab Biosimilar is currently being developed as a research grade antibody, which means it is intended for use in laboratory research and not for human use. This allows for further studies and optimization of the antibody before it can be used as a therapeutic agent. Conclusion Emerfetamab Biosimilar is a promising monoclonal antibody that targets the CD33 and CD3E proteins, which play a crucial role in the development and progression of cancer. Its potential to treat various types of cancer, including AML, MDS, ALL, and solid tumors, makes it a valuable addition to the current treatment options. With ongoing research and development, Emerfetamab Biosimilar has the potential to become a valuable therapeutic agent for cancer treatment in the future.

Emibetuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade, ProteoGenix, PX-TA1351

Description of Emibetuzumab Biosimilar - Anti-MET, RCCP2 mAb - Research Grade Introduction Emibetuzumab Biosimilar, also known as Anti-MET, RCCP2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancers. This biosimilar is designed to target the MET receptor, which is overexpressed in many cancer types and plays a crucial role in tumor growth and progression. In this article, we will discuss the structure, activity, and potential applications of Emibetuzumab Biosimilar as a research-grade antibody. Structure of Emibetuzumab Biosimilar Emibetuzumab Biosimilar is a recombinant, humanized monoclonal antibody that is produced in mammalian cells. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding Fab regions at the end of the arms and a constant Fc region at the base. The Fab regions are responsible for binding to the MET receptor, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Emibetuzumab Biosimilar The main target of Emibetuzumab Biosimilar is the MET receptor, a tyrosine kinase receptor that is activated by its ligand, hepatocyte growth factor (HGF). Overexpression of MET has been observed in various cancers, including renal cell carcinoma, non-small cell lung cancer, and gastric cancer, and is associated with poor prognosis and resistance to treatment. Emibetuzumab Biosimilar binds to the extracellular domain of MET and blocks its activation by HGF, thereby inhibiting downstream signaling pathways that promote tumor growth and metastasis. In addition to its direct anti-tumor activity, Emibetuzumab Biosimilar has been shown to enhance the effectiveness of other anti- cancer therapies. Studies have demonstrated that the combination of Emibetuzumab Biosimilar with chemotherapy or other targeted therapies can lead to improved tumor regression and prolonged survival in animal models. This is thought to be due to the ability of Emibetuzumab Biosimilar to sensitize cancer cells to the effects of other treatments by inhibiting the MET signaling pathway. Applications of Emibetuzumab Biosimilar Emibetuzumab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including renal cell carcinoma, non-small cell lung cancer, and gastric cancer. As a research-grade antibody, it is also widely used in preclinical studies to investigate the role of the MET receptor in cancer biology and to assess the potential of Emibetuzumab Biosimilar as a therapeutic agent. In addition to its potential as a monotherapy, Emibetuzumab Biosimilar is being studied in combination with other anti- cancer therapies. This includes combinations with chemotherapy, immune checkpoint inhibitors, and other targeted therapies. The goal of these studies is to identify the most effective treatment regimens for different types of cancer and to improve patient outcomes. Conclusion In summary, Emibetuzumab Biosimilar is a promising research-grade antibody that has the potential to be a valuable therapeutic agent for various types of cancer. Its unique mechanism of action, targeting the MET receptor, makes it a promising candidate for both monotherapy and combination therapy approaches. Ongoing clinical trials will provide further insights into the efficacy and safety of Emibetuzumab Biosimilar, and its potential to improve outcomes for cancer patients.

Emicizumab Biosimilar – Anti-F10, F9 activated form mAb – Research Grade, ProteoGenix, PX-TA1394

Description of Emicizumab Biosimilar - Anti-F10, F9 activated form mAb - Research Grade General information on Anti-F10/F9 activated form[Homo sapiens] (Emicizumab) Monoclonal Antibody Emicizumab is a humanized monoclonal antibody that mimics the function of coagulation factor VIII and has the ability to simultaneously bind to activated factors IX and X.

Emzotamig Biosimilar – Research Grade, ProteoGenix, PX-TA2476-100

Encelimab Biosimilar – Anti-LAG3, CD223 mAb – Research Grade, ProteoGenix, PX-TA1586

Description of Encelimab Biosimilar - Anti-LAG3, CD223 mAb - Research Grade Introduction Encelimab Biosimilar, also known as Anti-LAG3 or CD223 monoclonal antibody, is a research grade therapeutic antibody that targets the Lymphocyte Activation Gene 3 (LAG3) protein. LAG3 is a cell surface molecule that is primarily expressed on immune cells and plays a critical role in regulating immune responses. Encelimab Biosimilar is a promising new treatment option for various autoimmune diseases and cancers, and its unique structure and mechanism of action make it a highly sought-after therapeutic target. Structure of Encelimab Biosimilar Encelimab Biosimilar is a monoclonal antibody, meaning it is a laboratory-produced protein that is designed to mimic the function of natural antibodies in the body. It is composed of two heavy chains and two light chains, which are held together by disulfide bonds. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the end of each arm and a crystallizable fragment (Fc) at the base. The Fab regions of Encelimab Biosimilar are responsible for binding to the LAG3 protein, while the Fc region is responsible for activating immune cells and promoting antibody-mediated cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This dual mechanism of action makes Encelimab Biosimilar a potent therapeutic agent for targeting LAG3. Activity of Encelimab Biosimilar Encelimab Biosimilar works by binding to the LAG3 protein on the surface of immune cells, including T cells, B cells, and natural killer (NK) cells. This binding prevents LAG3 from interacting with its natural ligands, such as major histocompatibility complex (MHC) class II molecules, which are essential for immune cell activation and function. By blocking the interaction between LAG3 and its ligands, Encelimab Biosimilar helps to restore proper immune function and balance. It can also enhance the activity of other immune cells, such as T cells and NK cells, by promoting their activation and proliferation. In addition, the Fc region of Encelimab Biosimilar can trigger the destruction of LAG3-expressing cells through ADCC and ADCP, further contributing to its therapeutic activity. Applications of Encelimab Biosimilar Encelimab Biosimilar is currently being investigated for its potential in treating various autoimmune diseases and cancers. In autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, LAG3 is overexpressed and plays a role in suppressing immune responses. By targeting LAG3, Encelimab Biosimilar can help to restore immune balance and alleviate disease symptoms. In cancer, LAG3 is often expressed on tumor-infiltrating immune cells, which can suppress anti-tumor immune responses. By blocking LAG3, Encelimab Biosimilar can enhance the activity of immune cells against cancer cells and potentially improve the efficacy of other cancer treatments, such as chemotherapy and immunotherapy. Conclusion Encelimab Biosimilar, also known as Anti-LAG3 or CD223 monoclonal antibody, is a promising new therapeutic agent that targets the LAG3 protein. Its unique structure and mechanism of action make it a potent therapeutic target for various autoimmune diseases and cancers. Ongoing research and clinical trials will further elucidate the full potential of Encelimab Biosimilar in treating these diseases and improving patient outcomes.

Enfortumab Biosimilar – Anti-PVRL4 mAb – Research Grade, ProteoGenix, PX-TA1333

Description of Enfortumab Biosimilar - Anti-PVRL4 mAb - Research Grade General information on Anti-PVRL4[Homo sapiens] (Enfortumab) Monoclonal Antibody Enfortumab is a human monoclonal antibody that targets Nectin-4. It has been used as an antibody drug conjugate (ADC), Enfortumab vedotin to treat patients with advanced, treatment-resistant urothelial cancers.It has been marketed under the tradename Padcev.

Enoblituzumab Biosimilar – Anti-CD276, B7-H3 mAb – Research Grade, ProteoGenix, PX-TA1410

Description of Enoblituzumab Biosimilar - Anti-CD276, B7-H3 mAb - Research Grade General information on Anti-CD276/B7-H3[Homo sapiens] (Enoblituzumab) Monoclonal Antibody Enoblituzumab is investigated for the treatment of B7-H3-expressing Solid Tumors.

Ensavatatug Biosimilar – Research Grade, ProteoGenix, PX-TA2477-100

Epcoritamab Biosimilar – Anti-CD3E;MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1587

Description of Epcoritamab Biosimilar - Anti-CD3E;MS4A1, CD20 mAb - Research Grade Introduction Epcoritamab Biosimilar is a novel monoclonal antibody (mAb) that targets three important proteins, namely CD3E, MS4A1, and CD20. This biosimilar is being developed as a potential treatment for various diseases, including autoimmune disorders, cancer, and inflammatory conditions. In this article, we will provide a detailed scientific description of Epcoritamab Biosimilar, including its structure, activity, and potential applications. Structure of Epcoritamab Biosimilar Epcoritamab Biosimilar is a chimeric monoclonal antibody, meaning it is composed of both human and non-human components. The antibody is made up of two parts – a constant region and a variable region. The constant region is derived from human antibodies, while the variable region is derived from non-human sources, such as mice or rats. This structure allows Epcoritamab Biosimilar to bind to its target proteins with high specificity and affinity. The constant region of Epcoritamab Biosimilar is responsible for the effector functions of the antibody, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). These effector functions play a crucial role in the antibody’s ability to eliminate target cells. Activity of Epcoritamab Biosimilar Epcoritamab Biosimilar targets three key proteins – CD3E, MS4A1, and CD20. CD3E is a protein that is found on the surface of T cells, a type of immune cell that plays a crucial role in the body’s immune response. MS4A1, also known as CD20, is a protein found on the surface of B cells, another type of immune cell involved in the immune response. CD20 is also expressed on the surface of certain cancer cells, making it an attractive therapeutic target. Epcoritamab Biosimilar binds to CD3E and CD20 on the surface of T and B cells, respectively, leading to the activation of these cells. This activation triggers a cascade of events that ultimately results in the destruction of the target cells. Additionally, Epcoritamab Biosimilar also binds to MS4A1 on the surface of cancer cells, leading to their destruction. Applications of Epcoritamab Biosimilar Epcoritamab Biosimilar has several potential applications in the field of medicine. Its ability to target CD3E and CD20 makes it a promising candidate for the treatment of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. By targeting these proteins, Epcoritamab Biosimilar can suppress the activity of T and B cells, which are responsible for the development of these disorders. Furthermore, Epcoritamab Biosimilar has shown promising results in the treatment of various types of cancer. By targeting CD20 on the surface of cancer cells, Epcoritamab Biosimilar can induce their destruction, leading to tumor regression. It has shown particular efficacy in the treatment of B-cell malignancies, such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In addition to its therapeutic applications, Epcoritamab Biosimilar also has potential uses in research and diagnostic settings. Its ability to specifically target CD3E, MS4A1, and CD20 makes it a valuable tool for studying the functions of these proteins and their role in various diseases. Conclusion In conclusion, Epcoritamab Biosimilar is a chimeric monoclonal antibody that targets CD3E, MS4A1, and CD20. Its unique structure and activity make it a promising candidate for the treatment of autoimmune disorders and various types of cancer. Additionally, its potential uses in research and diagnostics make it a valuable tool for further understanding the functions of these proteins. With ongoing research and development, Epcoritamab Biosimilar has the potential to improve the lives of patients suffering from these diseases.

Erfonrilimab Biosimilar – Anti-CD274;CTLA4 mAb – Research Grade, ProteoGenix, PX-TA1665

Description of Erfonrilimab Biosimilar - Anti-CD274;CTLA4 mAb - Research Grade Erfonrilimab Biosimilar: A Promising Antibody for Targeting CD274 and CTLA4 Erfonrilimab Biosimilar, also known as Anti-CD274,CTLA4 mAb, is a novel antibody currently in development for its potential therapeutic applications. This biosimilar antibody is designed to target two important immune checkpoint molecules, CD274 (also known as PD-L1) and CTLA4, which play a crucial role in regulating the immune response. In this article, we will provide a detailed scientific description of the structure, activity, and potential applications of Erfonrilimab Biosimilar. Structure of Erfonrilimab Biosimilar Erfonrilimab Biosimilar is a monoclonal antibody (mAb) that is produced through recombinant DNA technology. It is a biosimilar version of the original antibody, which means it has a highly similar structure and function to the reference product. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are made up of constant and variable regions, while the light chains only have variable regions. The variable regions of the antibody are responsible for recognizing and binding to its target molecules, CD274 and CTLA4. These regions are highly specific and have a unique three-dimensional structure that allows them to bind to their targets with high affinity. The constant regions, on the other hand, are responsible for the effector functions of the antibody, such as activating the immune response and triggering cell death in target cells. Activity of Erfonrilimab Biosimilar Erfonrilimab Biosimilar is a dual-targeting antibody that binds to both CD274 and CTLA4. CD274 is a protein that is expressed on the surface of various cells, including cancer cells, and plays a key role in suppressing the immune response. By binding to CD274, Erfonrilimab Biosimilar blocks its interaction with its receptor, PD-1, on T cells, thereby preventing the suppression of the immune response. This results in the activation of T cells and the enhancement of their anti-tumor activity. Similarly, CTLA4 is another immune checkpoint molecule that is expressed on the surface of T cells. It plays a critical role in regulating the immune response by inhibiting the activation of T cells. By binding to CTLA4, Erfonrilimab Biosimilar blocks its inhibitory activity, leading to the activation of T cells and the enhancement of their anti-tumor activity. Moreover, the binding of Erfonrilimab Biosimilar to CTLA4 also promotes the activation of other immune cells, such as natural killer cells and macrophages, which further contribute to the anti-tumor response. Potential Applications of Erfonrilimab Biosimilar Erfonrilimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for its potential therapeutic applications. The primary indication for this biosimilar antibody is in the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and bladder cancer. By targeting CD274 and CTLA4, Erfonrilimab Biosimilar has the potential to enhance the anti-tumor immune response and improve the outcomes of cancer treatment. In addition to cancer, Erfonrilimab Biosimilar may also have potential applications in other diseases where immune dysregulation plays a role. This includes autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, as well as infectious diseases, such as HIV and hepatitis B. By modulating the immune response, Erfonrilimab Biosimilar has the potential to improve the outcomes of these diseases and provide a new treatment option for patients. Conclusion In summary, Erfonrilimab Biosimilar is a promising antibody that targets two important immune checkpoint molecules, CD274 and CTLA4. Its unique structure and activity make